We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,179.00 +11.50 (+0.22%) Dow Futures
38,310.00 +72.00 (+0.19%) Nasdaq Futures
18,223.75 +44.50 (+0.24%) Russell 2000 Futures
2,030.00 +10.20 (+0.50%) Crude Oil
85.41 -0.25 (-0.29%) Gold
2,371.20 -2.90 (-0.12%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 126.15 |
| Open | 127.04 |
| Bid | 123.00 x 800 |
| Ask | 131.24 x 800 |
| Day's Range | 125.10 - 127.11 |
| 52 Week Range | 99.14 - 133.10 |
| Volume | |
| Avg. Volume | 8,418,320 |
| Market Cap | 318.503B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 898.14 |
| EPS (TTM) | 0.14 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 3.08 (2.45%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 137.02 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
Related Research
- Merck & Company, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.RatingFair ValueEconomic Moat9 days agoMorningstar
Simply Wall St.Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?
Merck's (NYSE:MRK) stock is up by 7.0% over the past three months. However, its weak financial performance indicators...
ZacksModerna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
InvestorPlaceGolden Years Gainers: 3 Stocks to Fund Your Dream Retirement
Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started. With compounding interest and dividend growth, investors who take investing and saving for retirement seriously can become very profitable over a number of decades. Here are a number of stocks that provide investors with a fantastic start to a long-term investment portfolio for growth as well as overall income g
InvestorPlaceThe 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden’s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country’s economic resilience, bolstered by substantial fiscal s
Insider Monkey10 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
- Simply Wall St.
The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...
ZacksMerck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.
BioPharma DiveMerck puts KRAS cancer drug competitor to the test
A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.
Business WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| PFE Pfizer Inc. | |||
| JNJ Johnson & Johnson | |||
| PG The Procter & Gamble Company | |||
| BMY Bristol-Myers Squibb Company | |||
| VZ Verizon Communications Inc. |
Similar to MRK
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| JNJ Johnson & Johnson | |||
| BMY Bristol-Myers Squibb Company | |||
| ABBV AbbVie Inc. | |||
| AMGN Amgen Inc. | |||
| PFE Pfizer Inc. |
Analyst Price Targets (25)
Upgrades & Downgrades
| Maintains | Berenberg: Buy to Buy | 4/8/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 | |
| Reiterates | Truist Securities: Buy to Buy | 3/28/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2024 | |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 3/27/2024 |
Company Profile
126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 70,000
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
